All news
Positive impactCompany

Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% return

Economic Times 4 hrs ago·27 Jul 2026, 2:04 am

Nuvama has raised its target price for Dr Lal PathLabs, citing strong growth prospects in the diagnostics sector. The brokerage firm has upgraded its rating to 'Buy' and set a new price target of Rs 2,140, suggesting a potential upside of around 21% from the current market price. This positive outlook is based on the company's ability to maintain its market leadership and expand its service network.

For investors eyeing long-term opportunities, Dr Lal PathLabs represents a key player in the healthcare space. The stock's performance will hinge on the company's execution of its expansion plans and its ability to navigate competitive pressures. Keeping an eye on quarterly earnings and new service launches will be crucial for assessing the stock's future trajectory.

IDFC First Bank is also highlighted in this list as a potential long-term bet. The bank has been focusing on improving its asset quality and expanding its customer base. Investors should monitor the bank's credit growth and net interest margin trends to gauge its progress in the financial sector.

Excerpt from Economic Times

​Nuvama on Dr Lal PathLabs Nuvama on Dr Lal PathLabs: Buy| Target Rs 2140 (vs Rs 1900)| LTP Rs 1756| Potential Upside 21% Nuvama has reiterated its 'Buy' rating on Dr Lal PathLabs and raised the target price to Rs 2,140 from Rs 1,900, implying a potential upside of 21% from the current market price of Rs 1,756.…
Read the original at Economic Times

Affected stocks

Bullish1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns IDFC First Bank (IDFCFIRSTB).
  • Category: Company.
  • AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for IDFC First Bank. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Economic Times.

More Company news

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.